New combo inhaler boosts breathing in uncontrolled asthma
NCT ID NCT02296411
First seen Apr 24, 2026 · Last updated May 22, 2026 · Updated 6 times
Summary
This study tested whether adding an extra medication (glycopyrrolate) to a standard asthma inhaler (QVAR) helps people whose asthma is not well controlled. 98 adults with asthma took either the combination or a placebo for 6 weeks. Results showed that the combination improved lung function over 12 hours compared to placebo. This approach aims to better control asthma symptoms, not cure the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ASTHMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Chiesi Clinical Trial Site 0101
Sofia, 1000, Bulgaria
-
Chiesi Clinical Trial Site 0102
Sofia, 1431, Bulgaria
-
Chiesi Clinical Trial Site 0103
Sofia, 1431, Bulgaria
-
Chiesi Clinical Trial Site 0106
Sevlievo, 5400, Bulgaria
-
Chiesi Clinical Trial Site 0107
Rousse, 7002, Bulgaria
-
Chiesi Clinical Trial Site 0108
Sofia, 1407, Bulgaria
-
Chiesi Clinical Trial Site 0109
Sofia, 1336, Bulgaria
-
Chiesi Clinical Trial Site 0201
Berlin, D-12165, Germany
-
Chiesi Clinical Trial Site 0202
Leipzig, 04357, Germany
-
Chiesi Clinical Trial Site 0203
Leipzig, 04207, Germany
-
Chiesi Clinical Trial Site 0206
Magdeburg, 39112, Germany
-
Chiesi Clinical Trial Site 0207
Radebeul, 01445, Germany
-
Chiesi Clinical Trial Site 0208
Witten, 58452, Germany
-
Chiesi Clinical Trial Site 0301
Pisa, 56124, Italy
-
Chiesi Clinical Trial Site 0303
Pordenone, 33170, Italy
-
Chiesi Clinical Trial Site 0304
Pisa, 56124, Italy
-
Chiesi Clinical Trial Site 0306
Brescia, 25123, Italy
-
Chiesi Clinical Trial Site 0404
Assen, 9401 RK, Netherlands
-
Chiesi Clinical Trial Site 0405
Helmond, 5707 HA, Netherlands
-
Chiesi Clinical Trial Site 0501
Bialystok, 15-010, Poland
-
Chiesi Clinical Trial Site 0502
Bialystok, 15-351, Poland
-
Chiesi Clinical Trial Site 0503
Elblag, 82-300, Poland
-
Chiesi Clinical Trial Site 0504
Krakow, 31-011, Poland
-
Chiesi Clinical Trial Site 0505
Wroclaw, 53-310, Poland
-
Chiesi Clinical Trial Site 0506
Zgierz, 95-100, Poland
-
Chiesi Clinical Trial Site 0507
Krakow, 30-349, Poland
-
Chiesi Clinical Trial Site 0510
Lodz, 90-252, Poland
-
Chiesi Clinical Trial Site 0512
Lodz, 90-141, Poland
Conditions
Explore the condition pages connected to this study.